http://nz.biz.yahoo.com//090713/24/dbhu.html
Research and Markets (http://www.researchandmarkets.com/research/d5a2ca/singapore_pharmace)
has announced the addition of the "Singapore
Pharmaceuticals and Healthcare Report Q4 2009" report to their
offering.
The Singapore Pharmaceuticals and Healthcare Report provides industry
professionals and strategists, corporate analysts, pharmaceutical
associations, government departments and regulatory bodies with
independent forecasts and competitive intelligence on Singapore's
pharmaceuticals and healthcare industry
Singapore now represents an average proposition for multinational
pharmaceutical companies operating in Asia Pacific, behind established
leaders such as Japan and South Korea. The country slipped from fourth
in the Q209 regional Business Environment Rankings (BER) matrix to sixth
in Q309 and further to eighth in Q409. Positives include a 100% urban
market and a predictable operating climate, including political and
economic stability. However, its limited growth potential, due to a
small population size, as well as the current economic conditions
(despite the expected full recovery from 2012), have conspired to
negatively impact Singapore's attractiveness. In local currency terms,
we forecasts only a marginal compound annual growth rate (CAGR) of
1.40%, with the market at consumer prices rising from SGD791mn
(US$561mn) in 2008 to SGD848mn (US$606mn) in 2013.
An additional challenge is the chronic shortage of pharmacists, with
authorities striving to recruit professionals from abroad. In May 2009,
the Singapore Pharmacy Council (SPC) introduced a new professional exam
for foreign-trained pharmacists, in order to ensure high ethical
standards in the sector. Around the same time, SPC introduced 'inactive'
status for pharmacies, with those that are not practicing any longer
having to pay only a portion of the retention fee. The change has been
introduced in a bid to encourage pharmacists to remain on the register
in Singapore.
Still, healthcare modernisation and the expansion of medical facilities,
especially for the elderly, will continue to provide an impetus for
growth. In the meantime, the government remains committed to providing
incentives for foreign direct investment (FDI) in biosciences. In 2008,
US$500mn was invested by foreign players in Singapore's biomedical
sciences sector, according to Singapore's Economic Development Board
(EDB), with the government targeting US$17bn in biosciences
manufacturing output by 2015, up from US$4.56bn in 2000). This goal is
likely to be achieved, given the news that both UKbased GlaxoSmithKline
(GSK) and Swiss Lonza are investing in local manufacturing facilities
for the production of vaccines and cell-based therapeutics,
respectively. Similarly, the June 2009 inauguration of the new
Investigational Medicines Unit by the National University Hospital (NUH)
also aims to promote Singapore's attractiveness as a regional clinical
trials base.
In terms of recent epidemiological developments, AsiaOne reported a
drastic increase in the number of genital warts cases in Singapore,
which are caused by the human papilloma virus (HPV). An HPV vaccine is
already available in Singapore, as a protection against both genital
warts and cervical cancer, but only for females aged nine or over.
Experts are pushing for the vaccine to be made available to males, who
comprise the majority of genital warts cases. By early August 2009,
Singapore also recorded nine human deaths from the swine flu virus, with
the authorities reporting that they are capable of containing the rising
number of A (N1H1) cases.
Key Topics Covered:
Executive Summary
Swot Analysis
Pharmaceutical Business Environment Ratings
Singapore - Market Summary
Regulatory Regime
Industry Trends And Developments
Industry Forecast Scenario
Competitive Landscape
Company Profiles
Country Snapshot: Singapore Demographic Data
Bmi Methodology
Companies Mentioned:
Pfizer
GlaxoSmithKline
Merck & Co
Novartis
Sanofi-Aventis
Baxter
Haw Par
SciGen
MerLion Pharmaceuticals
Veredus Laboratories
For more information visit http://www.researchandmarkets.com/research/d5a2ca/singapore_pharmace
Contact:Research and MarketsLaura Wood, Senior Manager,press@researchandmarkets.comU.S.
Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
|
